Viking Therapeutics to Participate in Upcoming Investor Conferences
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, announced its participation in two investor conferences. The William Blair Biotech Focus Conference will take place virtually from August 4-6, 2020, involving 1-on-1 meetings. Additionally, the BTIG Virtual Biotechnology Conference is scheduled for August 10-11, 2020, featuring a fireside chat on August 11 at 3:30 p.m. Eastern and 1-on-1 meetings. Viking is focused on developing therapies for metabolic disorders, including VK2809 for NASH and VK5211 for improving lean body mass.
- None.
- None.
SAN DIEGO, July 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences.
Details of the company's participation are as follows:
- William Blair Biotech Focus Conference 2020
Details: Viking management will participate in 1-on-1 meetings
Conference Date: August 4-6, 2020
Format: Virtual Conference
- BTIG Virtual Biotechnology Conference
Details: Viking management will participate in a fireside chat and 1-on-1 meetings
Conference Date: August 10-11, 2020
Fireside Chat Time/Date: 3:30 p.m. Eastern on Tuesday, August 11, 2020
Format: Virtual Conference
About Viking Therapeutics, Inc.
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).
Viking's other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo. Other programs also include VK0612, a first-in-class, orally available drug candidate in Phase 2 development for the treatment of type 2 diabetes as well as two earlier-stage programs targeting metabolic diseases and anemia. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.
View original content to download multimedia:http://www.prnewswire.com/news-releases/viking-therapeutics-to-participate-in-upcoming-investor-conferences-301101410.html
SOURCE Viking Therapeutics, Inc.
FAQ
What conferences is Viking Therapeutics participating in August 2020?
What is the time of Viking Therapeutics' fireside chat at the BTIG conference?
What therapies is Viking Therapeutics developing?
What is VK2809 used for in Viking Therapeutics' clinical trials?
What is the significance of the William Blair and BTIG conferences for VKTX investors?
